WED Foundation and XenoPort, Inc. Announce Launch of New “Patient Odyssey” Survey Assessing Day-to-Day Impact of RLS/WED on Both Patients and Loved Ones

Published: Sep 26, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ROCHESTER, Minn. & SANTA CLARA, Calif.--(BUSINESS WIRE)--The Willis-Ekbom Disease (WED) Foundation and XenoPort, Inc. (Nasdaq: XNPT) announced today that they have launched a new “Patient Odyssey” survey, aimed at measuring the challenges of long-term disease management, quality of life (QoL) impact and emotional burden associated with restless legs syndrome/Willis-Ekbom Disease (RLS/WED) among patients, as well as the impact of the disease on relationships with spouses or partners. The survey kicks off during this year’s National RLS/WED Awareness Week, dedicated to the continuation of education that improves diagnosis and treatment of the disease.

Help employers find you! Check out all the jobs and post your resume.

Back to news